This Phase I Proposal aims to maximize gene transfer by means of polymeric-based micellar and nanoparticulate delivery vehicles in order to elicit protective immunity against Brucella. In-vitro cell mediated cytotoxicity and in-vivo pathogen protection in a challenge test will be demonstrated. For Phase I Option we will further characterize the protective immunity by means of cellular and humoral responses and analyze the protective effect over an extended period of time.
Benefits: Development of protective (and therapeutic) vaccine against Brucella as a commercial product
Keywords: Polymeric Nanoparticle Cell-Mediated Cytotoxicity Humoral Cellular Responses Low Regulatory Burden P
